Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma

Journal of Pathology

Volumn 219, Issue 4, 2009, Pages 435-445

  Abubaker, Jehad ^a   Bavi, Prashant ^a   Al Haqawi, Wael ^a   Sultana, Mehar ^a   Al Harbi, Sayer ^a   Al Sanea, Nasser ^a   Abduljabbar, Alaa ^a   Ashari, Luai H ^a   Alhomoud, Samar ^a   Al Dayel, Fouad ^a   Uddin, Shahab ^a   Al Kuraya, Khawla S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Colorectal carcinoma; KRAS mutation; KRAS4A; KRAS4B; Tissue microarray

Indexed keywords

BIOLOGICAL MARKER; CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FLUOROURACIL; ISOPROTEIN; K RAS PROTEIN; NUCLEAR PROTEIN;

ADENOCARCINOMA; ADULT; AGE; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CODON; COLORECTAL CARCINOMA; CORRELATION FUNCTION; CYTOPLASM; DIAGNOSTIC VALUE; DISEASE SEVERITY; DNA SEQUENCE; FEMALE; GENDER; GENE MUTATION; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA SPLICING; TUMOR VOLUME; VALIDATION PROCESS;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADENOMA; ADULT; BASE SEQUENCE; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTESTINAL MUCOSA; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 72249091662     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2625     Document Type: Article

References (53)

1. Jass JR. Colorectal cancer: a multipathway disease. Crit Rev Oncogenesis 2006;12:273-287.
2. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-170.
3. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-532.
4. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nature Rev 2003;3:459-465.
5. Voice JK, Klemke RL, Le A, Jackson JH. Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J Biol Chem 1999;274:17164-17170. (Pubitemid 129519050)
6. Brooks DG, James RM, Patek CE, Williamson J, Arends MJ. Mutant K-ras enhances apoptosis in embryonic stem cells in combination with DNA damage and is associated with increased levels of p19(ARF). Oncogene 2001;20:2144-2152. (Pubitemid 32424008)
7. James RM, Arends MJ, Plowman SJ, Brooks DG, Miles CG, West JD, et al. K-ras proto-oncogene exhibits tumor suppressor activity as its absence promotes tumorigenesis in murine teratomas. Mol Cancer Res 2003;1:820-825.
8. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004;5:375-387. (Pubitemid 38482073)
9. Bourne HR, Sanders DA, McCormick F. The GTPase super-family: conserved structure and molecular mechanism. Nature 1991;349:117-127. (Pubitemid 21912023)
10. Mitin N, Rossman KL, Der CJ. Signaling interplay in Ras superfamily function. Curr Biol 2005;15:R563-R574. (Pubitemid 41026614)
11. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-1074.
12. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987;327:293-297.
13. Capon DJ, Seeburg PH, McGrath JP, Hayflick JS, Edman U, Levinson AD, et al. Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature 1983;304:507-513.
14. Welman A, Burger MM, Hagmann J. Structure and function of the C-terminal hypervariable region of K-Ras4B in plasma membrane targeting and transformation. Oncogene 2000;19:4582-4591. (Pubitemid 30777626)
15. Plowman SJ, Arends MJ, Brownstein DG, Luo F, Devenney PS, Rose L, et al. The K-Ras 4A isoform promotes apoptosis but does not affect either lifespan or spontaneous tumor incidence in aging mice. Exp Cell Res 2006;312:16-26. (Pubitemid 41668588)
16. Patek CE, Arends MJ, Rose L, Luo F, Walker M, Devenney PS, et al. The pro-apoptotic K-Ras 4A proto-oncoprotein does not affect tumorigenesis in the ApcMin/+ mouse small intestine. BMC Gastroenterol 2008;8:24. (Pubitemid 351998103)
17. Baisse B, Bouzourene H, Saraga EP, Bosman FT, Benhattar J. Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer 2001;93:346-352. (Pubitemid 32592052)
18. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-4689. (Pubitemid 19213607)
19. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
20. Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, Pachen MM, et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 2003;24:703-710. (Pubitemid 36592405)
21. Bavi P, Jehan Z, Atizado V, Al-Dossari H, Al-Dayel F, Tulbah A, et al. Prevalence of fragile histidine triad expression in tumors from Saudi Arabia: a tissue microarray analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1708-1718. (Pubitemid 44497108)
22. Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Siraj AK, Al- Sanea N, et al. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene 2008;27:3539-3545. (Pubitemid 351793794)
23. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-5257. (Pubitemid 28521189)
24. Uddin S, Siraj AK, Al-Rasheed M, Ahmed M, Bu R, Myers JN, et al. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J Clin Endocrinol Metab 2008;93:4088-4097.
25. Uddin S, Bavi P, Hussain AR, Alsbeih G, Al-Sanea N, Abduljabbar A, et al. Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. Carcinogenesis 2009;DOI:10.1093/carcin/bgp145.
26. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bioinformatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-7259. (Pubitemid 39487712)
27. Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, et al. FOXA1 expression in breast cancer - correlation with luminal subtype A and survival. Clin Cancer Res 2007;13:4415-4421. (Pubitemid 47219708)
28. McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 2005;11:5188-5194. (Pubitemid 41003705)
29. Grossman SR, Lyle S, Resnick MB, Sabo E, Lis RT, Rosinha E, et al. p66 Shc tumor levels show a strong prognostic correlation with disease outcome in stage IIA colon cancer. Clin Cancer Res 2007;13:5798-5804. (Pubitemid 47583903)
30. Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, et al. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Res 2008;68:3379-3388.
31. Bavi P, Abubaker J, Hussain A, Sultana M, Al-Dayel F, Uddin S, et al. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. Hum Pathol 2008;39:885-894.
32. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002;30:e36.
33. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-3995.
34. Beranek M, Bures J, Palicka V, Jandik P, Langr F, Nejedla E. A relationship between K-ras gene mutations and some clinical and histologic variables in patients with primary colorectal carcinoma. Clin Chem Lab Med 1999;37:723-727. (Pubitemid 29423987)
35. Urosevic N, Krtolica K, Skaro-Milic A, Knezevic-Usaj S, Dujic A. Prevalence of G-to-T transversions among K-ras oncogene mutations in human colorectal tumors in Yugoslavia. Int J Cancer 1993;54:249-254. (Pubitemid 23154890)
36. Martinez-Garza SG, Nunez-Salazar A, Calderon-Garciduenas AL, Bosques-Padilla FJ, Niderhauser-Garcia A, Barrera-Saldana HA. Frequency and clinicopathology associations of K-ras mutations in colorectal cancer in a northeast Mexican population. Digest Dis (Basel) 1999;17:225-229. (Pubitemid 30198256)
37. Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol- 3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008;122:2255-2259. (Pubitemid 351542328)
38. Conzelmann M, Linnemann U, Berger MR. K-ras codon 12 and 13 mutations are correlated with differential patterns of tumor cell dissemination in colorectal cancer patients. Int J Oncol 2004;24:1537-1544.
39. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001;85:692-696.
40. Span M, Moerkerk PT, De Goeij AF, Arends JW. A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer 1996;69:241-245. (Pubitemid 26233305)
41. Cerottini JP, Caplin S, Saraga E, Givel JC, Benhattar J. The type of K-ras mutation determines prognosis in colorectal cancer. Am J Surg 1998;175:198-202. (Pubitemid 28173710)
42. Bouzourene H, Gervaz P, Cerottini JP, Benhattar J, Chaubert P, Saraga E, et al. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 2000;36:1008-1015. (Pubitemid 30316426)
43. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prevention 2000;9:1193-1197. (Pubitemid 30844068)
44. Kressner U, Bjorheim J, Westring S, Wahlberg SS, Pahlman L, Glimelius B, et al. Ki-ras mutations and prognosis in colorectal cancer. Eur J Cancer 1998;34:518-521. (Pubitemid 28179348)
45. Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri MA, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002;13:1438-1446.
46. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene 2003;22:8999-9006.
47. Plowman SJ, Berry RL, Bader SA, Luo F, Arends MJ, Harrison DJ, et al. K-ras 4A and 4B are co-expressed widely in human tissues, and their ratio is altered in sporadic colorectal cancer. J Exp Clin Cancer Res 2006;25:259-267. (Pubitemid 44113872)
48. Jehan Z, Bavi P, Sultana M, Abubaker J, Bu R, Hussain A, et al. Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer. J Pathol 2009;219:337-346.
49. Hershko DD, Shapira M. Prognostic role of p27Kip1 deregulation in colorectal cancer. Cancer 2006;107:668-675. (Pubitemid 44232659)
50. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nature Med 2002;8:1145-1152. (Pubitemid 35175970)
51. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nature Med 2002;8:1153-1160. (Pubitemid 35175971)
52. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009;69:1851-1857.
53. Sazani P, Kole R. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest 2003;112:481-486. (Pubitemid 38056330)